Use of Atezolizumab And Bevacizumab in Unrespectable Hepatocellular Carcinoma
Significant studies on Atezolizumab and Bevacizumab reveal promising results in treating patients with Unrespectable Hepatocellular Carcinoma. Let’s dissect the use and study of Atezolizumab and Bevacizumab in Unrespectable Hepatocellular Carcinoma.
Hepatocellular Carcinoma is a cancer that starts in your liver. According to WebMD, if caught early treatment and surgery could cure Hepatocellular Carcinoma.
Roche evaluated the efficacy and safety of Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) as a treatment for people with unresectable hepatocellular carcinoma. Hepatocellular Carcinoma is the most common form of liver cancer, accounting for over 75% of cases.
Study of Atezolizumab And Bevacizumab in Unrespectable Hepatocellular Carcinoma
The study showed a confirmed response rate of 36% in patients treated with the Tecentriq / Avastin combination in unresectable hepatocellular carcinoma who had not received prior systemic treatment. The combination of Tecentriq and Avastin has been shown to reduce the risk of disease by 45% compared to Tecentriq as monotherapy.
Sandra Horning, Roche’s chief medical officer, said: “We are encouraged by these latest results, which show progression-free survival and confirmed rates in people with unresectable hepatocellular carcinoma.” Patients with unresectable hepatocellular carcinoma (HCC) have been able to maintain a better quality of life with the combination of atezolizumab and bevacizumab compared to sorafenib.
Because it is important?
The trial has already shown that first-line therapy with atezolizumab and bevacizumab has a survival benefit compared to sorafenib in patients with unresectable HCC. In a palliative context, where life expectancy is limited, it is important to take into account the patients’ point of view on the general clinical benefit, in order to maintain the remaining quality of life.
Patients with unresectable HCC who had not previously received any systemic therapy (n = 501) were randomized (2: 1) to receive the combination of atezolizumab and bevacizumab or sorafenib.
Impairment time (TTD) was defined as a 10-point reduction in key outcomes reported by patients, compared to inclusion.
Compared with sorafenib, the combination of atezolizumab and bevacizumab delayed TTD in patient-reported quality of life (median TTD: 11.2 months, versus 3.6 months; risk ratio [RR]: 0.63 [95% CI: 0.46–0.85]), physical functioning (mean TTD: 13.1 months, versus 4.9 months; RR: 0.53 [95% CI: 0.39–0.73]) and home and professional functioning (median TTD: 9.1 months , versus 3.6 months; RR: 0.62 [95% CI: 0.46-0.84]).
Fewer patients receiving the combination of atezolizumab and bevacizumab experienced clinically relevant worsening of specific symptoms, including loss of appetite, fatigue, pain, and diarrhea, compared to sorafenib.
Dr. Craig Lockhart, MD, of the Sylvester Comprehensive Cancer Center at the University of Miami, Florida, said: “We will have to factor in the cost, but it will be balanced with the data reported by the patients we just saw.”
Read more Science News on WeeklyReviewer!